Amplity, Inc.
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
We are pleased to present the exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. This series provides peer-to-peer physician perspectives on emerging data in the treatment of hormone receptor (HR)-positive/HER2-negative early to metastatic breast cancer. Sponsored by Lilly
Copyright 2026 Amplity, Inc.
Sign up to track rankings and reviews from Spotify, Apple Podcasts and more.